222 related articles for article (PubMed ID: 23436619)
1. Design of libraries targeting protein-protein interfaces.
Fry D; Huang KS; Di Lello P; Mohr P; Müller K; So SS; Harada T; Stahl M; Vu B; Mauser H
ChemMedChem; 2013 May; 8(5):726-32. PubMed ID: 23436619
[TBL] [Abstract][Full Text] [Related]
2. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment.
Zhao Y; Aguilar A; Bernard D; Wang S
J Med Chem; 2015 Feb; 58(3):1038-52. PubMed ID: 25396320
[TBL] [Abstract][Full Text] [Related]
3. An integrated in silico screening strategy for identifying promising disruptors of p53-MDM2 interaction.
Sirous H; Chemi G; Campiani G; Brogi S
Comput Biol Chem; 2019 Dec; 83():107105. PubMed ID: 31473433
[TBL] [Abstract][Full Text] [Related]
4. A re-examination of the MDM2/p53 interaction leads to revised design criteria for novel inhibitors.
Vasilevich NI; Afanasyev II; Kovalskiy DA; Genis DV; Kochubey VS
Chem Biol Drug Des; 2014 Nov; 84(5):585-92. PubMed ID: 24797588
[TBL] [Abstract][Full Text] [Related]
5. Probing Protein Surfaces: QSAR Analysis with Helix Mimetics.
Azzarito V; Rowell P; Barnard A; Edwards TA; Macdonald A; Warriner SL; Wilson AJ
Chembiochem; 2016 Apr; 17(8):768-73. PubMed ID: 26690307
[TBL] [Abstract][Full Text] [Related]
6. Molecular interaction fields and 3D-QSAR studies of p53-MDM2 inhibitors suggest additional features of ligand-target interaction.
Dezi C; Carotti A; Magnani M; Baroni M; Padova A; Cruciani G; Macchiarulo A; Pellicciari R
J Chem Inf Model; 2010 Aug; 50(8):1451-65. PubMed ID: 20726601
[TBL] [Abstract][Full Text] [Related]
7. Small molecular weight protein-protein interaction antagonists: an insurmountable challenge?
Dömling A
Curr Opin Chem Biol; 2008 Jun; 12(3):281-91. PubMed ID: 18501203
[TBL] [Abstract][Full Text] [Related]
8. Searching for Dual Inhibitors of the MDM2-p53 and MDMX-p53 Protein-Protein Interaction by a Scaffold-Hopping Approach.
Zaytsev A; Dodd B; Magnani M; Ghiron C; Golding BT; Griffin RJ; Liu J; Lu X; Micco I; Newell DR; Padova A; Robertson G; Lunec J; Hardcastle IR
Chem Biol Drug Des; 2015 Aug; 86(2):180-9. PubMed ID: 25388787
[TBL] [Abstract][Full Text] [Related]
9. Small-molecule MDM2-p53 inhibitors: recent advances.
Zhang B; Golding BT; Hardcastle IR
Future Med Chem; 2015; 7(5):631-45. PubMed ID: 25921402
[TBL] [Abstract][Full Text] [Related]
10. 2,4,5-Tris(alkoxyaryl)imidazoline derivatives as potent scaffold for novel p53-MDM2 interaction inhibitors: Design, synthesis, and biological evaluation.
Bazanov DR; Pervushin NV; Savitskaya VY; Anikina LV; Proskurnina MV; Lozinskaya NA; Kopeina GS
Bioorg Med Chem Lett; 2019 Aug; 29(16):2364-2368. PubMed ID: 31196710
[TBL] [Abstract][Full Text] [Related]
11. Effective screening strategy using ensembled pharmacophore models combined with cascade docking: application to p53-MDM2 interaction inhibitors.
Xue X; Wei JL; Xu LL; Xi MY; Xu XL; Liu F; Guo XK; Wang L; Zhang XJ; Zhang MY; Lu MC; Sun HP; You QD
J Chem Inf Model; 2013 Oct; 53(10):2715-29. PubMed ID: 24050442
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of novel potent MDM2/p53 small-molecule inhibitors.
Ivanenkov YA; Vasilevski SV; Beloglazkina EK; Kukushkin ME; Machulkin AE; Veselov MS; Chufarova NV; Chernyaginab ES; Vanzcool AS; Zyk NV; Skvortsov DA; Khutornenko AA; Rusanov AL; Tonevitsky AG; Dontsova OA; Majouga AG
Bioorg Med Chem Lett; 2015 Jan; 25(2):404-9. PubMed ID: 25479770
[TBL] [Abstract][Full Text] [Related]
13. Phe19 modification of HDM2-p53 PPI inhibitors to alleviate CYP3A4 metabolism/mechanism-based inhibition liability.
Tian Y; Lahue BR; Ma Y; Nair LG; Pan W; Doll RJ; Guzi T; Ma Y; Wang Y; Bogen SL
Bioorg Med Chem Lett; 2022 Apr; 61():128625. PubMed ID: 35158044
[TBL] [Abstract][Full Text] [Related]
14. Recent Small-Molecule Inhibitors of the p53-MDM2 Protein-Protein Interaction.
Beloglazkina A; Zyk N; Majouga A; Beloglazkina E
Molecules; 2020 Mar; 25(5):. PubMed ID: 32156064
[TBL] [Abstract][Full Text] [Related]
15. Comparative validated molecular modeling of p53-HDM2 inhibitors as antiproliferative agents.
Mondal C; Halder AK; Adhikari N; Saha A; Saha KD; Gayen S; Jha T
Eur J Med Chem; 2015 Jan; 90():860-75. PubMed ID: 25535952
[TBL] [Abstract][Full Text] [Related]
16. Spiro-oxindoles as a Promising Class of Small Molecule Inhibitors of p53-MDM2 Interaction Useful in Targeted Cancer Therapy.
Gupta AK; Bharadwaj M; Kumar A; Mehrotra R
Top Curr Chem (Cham); 2017 Feb; 375(1):3. PubMed ID: 27943171
[TBL] [Abstract][Full Text] [Related]
17. Enhanced pharmacokinetic properties of 1,4-benzodiazepine-2,5-dione antagonists of the HDM2-p53 protein-protein interaction through structure-based drug design.
Parks DJ; LaFrance LV; Calvo RR; Milkiewicz KL; Marugán JJ; Raboisson P; Schubert C; Koblish HK; Zhao S; Franks CF; Lattanze J; Carver TE; Cummings MD; Maguire D; Grasberger BL; Maroney AC; Lu T
Bioorg Med Chem Lett; 2006 Jun; 16(12):3310-4. PubMed ID: 16600594
[TBL] [Abstract][Full Text] [Related]
18. Affinity-based screening of MDM2/MDMX-p53 interaction inhibitors by chemical array: identification of novel peptidic inhibitors.
Noguchi T; Oishi S; Honda K; Kondoh Y; Saito T; Kubo T; Kaneda M; Ohno H; Osada H; Fujii N
Bioorg Med Chem Lett; 2013 Jul; 23(13):3802-5. PubMed ID: 23726030
[TBL] [Abstract][Full Text] [Related]
19. Inhibitors of the p53/hdm2 protein-protein interaction-path to the clinic.
Carry JC; Garcia-Echeverria C
Bioorg Med Chem Lett; 2013 May; 23(9):2480-5. PubMed ID: 23541651
[TBL] [Abstract][Full Text] [Related]
20. How To Design a Successful p53-MDM2/X Interaction Inhibitor: A Thorough Overview Based on Crystal Structures.
Estrada-Ortiz N; Neochoritis CG; Dömling A
ChemMedChem; 2016 Apr; 11(8):757-72. PubMed ID: 26676832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
